AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04828200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasound
Description: The ultrasonographic assesment will be used to examine the rectus femoris, gastrocnemius medailalis and rectus abdominis subcutaneous and muscle thickness. Additionally, fascicle length and pennation angle were measured between the two parallel aponeuroses of the gastrocnemius muscle (bulkiest part of medial head) in the longitudinal view when subjects were in prone position with their ankles at 90°.
Study NCT04828200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-X-ray absorptiometry
Description: The muscle masses of the patients were evaluated by measuring the fat mass (Fat Mass-FM), fat mass index (FMI), lean body mass (LBM) and skeletal muscle index (SMI) calculated by DEXA. Appendicular muscle mass (ASM) is calculated by summing the lean soft tissue of the two upper limbs and the two lower limbs. Skeletal muscle mass index is calculated by dividing the appendicular lean mass by the square of the neck height \[SMI = ASM / height2 (kg / m2)\].
Study NCT04828200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Isokinetic dynamometer
Description: Quadriceps-hamstring Peak Torque (PT) values and the ratio of PT values to body weight (PT / VA) (at 60 and 180 ° / sec speeds) were evaluated with an isokinetic dynamometer
Study NCT03637985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistive exercise
Description: resistive exercise by elastic band for 12 weeks
Study NCT03637985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aerobic exercise in form of treadmill walking
Description: aerobic exercise in form of treadmill walking for 12 weeks
Study NCT03862846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REN001
Description: Once daily
Study NCT01401582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of Dementia Care Manager
Description: Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers.
Study NCT01809002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Processed Nerve Allograft (human)
Study NCT01809002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Nerve Cuff
Description: Bovine collagen based nerve cuff
Study NCT04070443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
Study NCT04070443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
Study NCT00776126 — intervention group
Intervention type: DEVICE
Intervention: Digital Breast Tomosynthesis Exam
Description: Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
Study NCT02528383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vagifem
Description: Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life
Study NCT02293915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oligo-mannurarate 900mg
Description: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
Study NCT02293915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: simulant of sodium oligo-mannurarate capsule
Study NCT03802084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vactosertib/imatinib combination
Description: Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Melanoma (HAM) Immunotherapy
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02054520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study NCT00985946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat (LBH589)
Description: Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
Study NCT02238665 — intervention group
Intervention type: DEVICE
Intervention: Endomicroscopy
Study NCT02395874 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tDCS + speech therapy
Description: Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
Study NCT02395874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS + speech therapy
Description: Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
Study NCT03975205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: To measure bioavailabity of Doxil versus Doxorubicin
Study NCT03975205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: To measure bioavailabity of Doxil versus Doxorubicin
Study NCT02709096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-01, 1% Topical Gel
Description: topical gel, applied to the forehead, cheeks, nose and chin
Study NCT01396304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restore Calcium Alginate Dressing
Description: Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
Study NCT01396304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AquaCel Ag Wound Dressing
Description: Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
Study NCT02709096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPX-01 Vehicle Gel
Description: topical gel, applied to the forehead, cheeks, nose and chin
Study NCT04438577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine mucilage-ICG
Description: Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: perfalgan
Description: intravenous paracetamol
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perfalgan
Description: intravenous paracetamol
Study NCT02515877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy + curietherapy
Description: External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
Study NCT02515877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistide
Description: VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
Study NCT02515877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC= 2,5 (Calvert formula)
Study NCT00818649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
Study NCT00818649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 400 mg orally (po) every day on days 1-14 of a 21 day cycle
Study NCT02926144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscope with video
Description: Intubation with video-laryngoscope McGrath with use of the video feature
Study NCT02926144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope without video
Description: Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
Study NCT03513588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, 0 mg, 14 days, every 12 hours
Study NCT03513588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: tablet, 50 mg, 14 days, every 12 hours
Study NCT03513588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: tablet, 300 mg, 14 days, every 12 hours
Study NCT02922309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Training Via Telepractice
Description: Vocal Training Via Telepractice, delivered by integrated communication service
Study NCT02922309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Training Via face-to face practice
Description: Vocal Training Via face-to face practice at medical facilities
Study NCT02925637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FaCoT
Description: The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
Study NCT01600573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib in combination with weekly topotecan
Description: * Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary.
Study NCT00572390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oestrogen
Description: Cyclic oestrogen substitution therapy
Study NCT00572390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestrogen
Description: Cyclic oestrogen substitution therapy
Study NCT02490202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
Study NCT02490202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
Study NCT00282204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: antenatal hypnosis + audio compact disc on hypnosis
Study NCT00282204 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio compact disc on hypnosis
Study NCT01270971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Topical Solution, 5%
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Study NCT01270971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solution Vehicle
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Study NCT03618654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO
Study NCT03618654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02077569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
Study NCT02077569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5363
Description: Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
Study NCT00002570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
Study NCT00002570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: 20 mg/m2 IV - number of cycles is determined by patient and physician
Study NCT02875093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ADI-PEG 20
Description: Investigational Medicine
Study NCT02875093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
Study NCT00188175 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
Study NCT03200015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
Study NCT03188757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperglycaemic clamp
Description: 2h hyperglyceamic clamp
Study NCT01789736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG286 Ophthalmic Solution 0.5%
Description: PG286 Ophthalmic Solution
Study NCT01789736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 Ophthalmic Solution 0.5%
Description: AR-12286 Ophthalmic Solution 0.5%
Study NCT01789736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost Ophthalmic Solution 0.004%
Description: Travoprost Ophthalmic Solution 0.004%
Study NCT03942809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effectiveness
Description: Effectiveness and Practicability in anesthetized patient under controlled conditions
Study NCT04429997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of fibrosynovial tissue
Description: Remove of fibrosynovial tissue at the superior border of patella
Study NCT04429997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-removal of fibrosynovial tissue
Description: Do not remove of fibrosynovial tissue at the superior border of patella
Study NCT02394951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Anticonvulsant
Study NCT02394951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Anticonvulsant
Study NCT02394951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical, matching inactive substance
Study NCT02394951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical, matching inactive substance
Study NCT03201705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst + Tonic
Description: Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
Study NCT02739295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant granulocyte - colony stimulating factor
Study NCT02739295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Study NCT01911065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax™
Description: In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
Study NCT02343055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management and Self-Management Education
Description: A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
Study NCT02343055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Case Management and Self-Management Education
Description: A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
Study NCT02154789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polidocanol
Study NCT02154789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infra-red coagulation
Study NCT02154789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Study NCT02571049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11
Description: Sumatriptan 3 mg versus 6 mg
Study NCT02182557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL 801 CL Dry Syrup
Study NCT02182557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Fumarate Dry Syrup
Study NCT02182557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WAL 801 CL Dry Syrup placebo
Study NCT02182557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen Fumarate Dry Syrup placebo
Study NCT03253874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Pre-Op Testing for Cataract Surgeries
Description: Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
Study NCT00546130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00546130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00546130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin
Description: Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
Study NCT03846141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of room air for 20 min per day during 7 days